January 14, 2020
Company name: Mitsubishi Tanabe Pharma Corporation
Representative:

Masayuki Mitsuka
President & Representative Director

Code number:

4508, First Section, Tokyo Stock Exchange

Contact:

Yoshiaki Takai, Vice President,
Head of Corporate Communications Dept.
(TEL: +81-6-6205-5211)

Change in Representative Director
Osaka (January 14, 2020) – The Board of Directors of Mitsubishi Tanabe Pharma
Corporation has today approved the following proposal to appoint a new RepresentativeDirector.
1. Change in Representative Director (effective April 1, 2020)
New Role
Member of the BoardName

Current RoleMasayuki Mitsuka

President
Representative Director

President

Hiroaki Ueno

Member of the Board, Managing

Representative Director

Executive Officer, in charge of HumanResources Department, Legal & General
Affairs Department, InternationalBusiness Department, China Operations
Management Office, ASEAN Business,
Europe Operations Management Office,Public Affairs & Policy Department

2. Reason for the Change
In order to respond to rapid changes in the business environment, it is important toaccelerate global business expansion, acquire the latest technologies, and secure newbusiness opportunities. As Mitsubishi Tanabe Pharma will be formulating its next midterm management plan and moving to a new phase in fiscal 2020, the company decided
to transition to the next generation of management.
Under the new leadership structure, the company will strive to strengthen its
management and enhance its corporate value toward further progress.

13. Biography of the New Representative Director
Name:

Hiroaki Ueno, Ph.D.

Date of birth:

September 8, 1958 (61 years old)

Education:

Completed a masterʼs course at the Graduate School of
Bioscience and Biotechnology, Tokyo Institute of Technology

Number of company shares owned: 4,920
Professional Career:April 1983

Entered Mitsubishi Chemical Industries Ltd.

July 2005

General Manager of Medicinal Research Laboratories Ⅳ of Research
Department of Sohyaku Division of Mitsubishi Pharma Corporation

July 2006

General Manager of Chemistry Research Laboratories of Sohyaku andResearch Division of Mitsubishi Pharma Corporation

October 2007

General Manager of Chemistry Department Ⅱ of Medicinal Chemistry
Research Laboratories of Research Division of the Company

April 2010

General Manager of Medicinal Chemistry Research Laboratories Ⅱ of
Research Division of the Company

April 2012

General Manager of Medicinal Chemistry Research Laboratories Ⅱ of
Research Division of the Company

April 2014

Executive Officer, General Manager of Research Strategy & Planning
Department of Research Division of the Company

April 2015

Executive Officer, Division Manager of CMC Division (Chemistry,Manufacturing and Control) of the Company

April 2017

Executive Officer, Division Manager of Sohyaku. Innovative Research
Division of the Company

April 2018

Managing Executive Officer, Division Manager of Sohyaku. Innovative
Research Division, in charge of Intellectual Property and Contract
Department of the Company

April 2019

Managing Executive Officer, in charge of Human Resources
Department, General Affairs Department, International Business
Department, China Operations Management Office, ASEAN Business,
Europe Operations Management Office, Public Affairs & Policy
Department of the Company

June 2019

Member of the Board, Managing Executive Officer, in charge of
Human Resources Department, General Affairs Department,International Business Department, China Operations Management
Office, ASEAN Business, Europe Operations Management Office,Public Affairs & Policy Department of the Company

October 2019

Member of the Board, Managing Executive Officer, in charge of
Human Resources Department, Legal & General Affairs Department,2

International Business Department, China Operations Management
Office, ASEAN Business, Europe Operations Management Office,Public Affairs & Policy Department of the Company (Current)
April 2020

To be appointed President and Representative Director of theCompany

4. Planned Date of Change
April 1, 2020
-End-3